Marker Therapeutics (MRKR) Cash & Equivalents (2010 - 2026)

Marker Therapeutics (MRKR) has 17 years of Cash & Equivalents data on file, last reported at $14.9 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $14.9 million, up 8.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.9 million (up 8.93% YoY), and the FY2025 annual result was $16.1 million, down 16.28% from the prior year.
• Cash & Equivalents retreated to $14.9 million in Q1 2026 per MRKR's latest filing, from $16.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $28.6 million in Q1 2022 and troughed at $6.4 million in Q1 2023.
• A 5-year average of $15.4 million and a median of $15.1 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents plunged 77.65% in 2023, then surged 95.45% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $11.8 million in 2022, then climbed by 28.26% to $15.1 million in 2023, then gained by 27.01% to $19.2 million in 2024, then fell by 16.28% to $16.1 million in 2025, then decreased by 7.17% to $14.9 million in 2026.
• Business Quant data shows MRKR's Cash & Equivalents at $14.9 million in Q1 2026, $16.1 million in Q4 2025, and $17.6 million in Q3 2025.